TRCT
ABCL icon

Tower Research Capital (TRC)’s AbCellera Biologics ABCL Stock Holding History

Tower Research Capital (TRC)’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20K Sell
5,731
-14,344
-71% -$51.6K ﹤0.01% 3483
2025
Q4 		$68.7K Buy
20,075
+14,901
+288% +$66.5K ﹤0.01% 2205
2025
Q3 		$26K Sell
5,174
-413
-7% -$1.82K ﹤0.01% 3071
2025
Q2 		$19.2K Buy
5,587
+1,053
+23% +$2.62K ﹤0.01% 3706
2025
Q1 		$10.1K Sell
4,534
-7,676
-63% -$22K ﹤0.01% 3677
2024
Q4 		$35.8K Sell
12,210
-3,773
-24% -$10.5K ﹤0.01% 2780
2024
Q3 		$41.6K Buy
15,983
+5,203
+48% +$14.4K ﹤0.01% 2824
2024
Q2 		$31.9K Buy
10,780
+6,406
+146% +$24.2K ﹤0.01% 3436
2024
Q1 		$19.8K Sell
4,374
-1,911
-30% -$9.75K ﹤0.01% 3008
2023
Q4 		$35.9K Sell
6,285
-2,186
-26% -$10.1K ﹤0.01% 3329
2023
Q3 		$39K Sell
8,471
-40,076
-83% -$244K ﹤0.01% 2771
2023
Q2 		$314K Buy
48,547
+43,160
+801% +$295K 0.01% 1267
2023
Q1 		$41K Sell
5,387
-8,752
-62% -$79.5K ﹤0.01% 2668
2022
Q4 		$143K Sell
14,139
-1,551
-10% -$17.9K 0.01% 1552
2022
Q3 		$155K Buy
15,690
+10
+0.1% +$110 ﹤0.01% 2164
2022
Q2 		$167K Buy
15,680
+14,123
+907% +$120K ﹤0.01% 1909
2022
Q1 		$15K Buy
1,557
+755
+94% +$7.15K ﹤0.01% 3788
2021
Q4 		$12K Sell
802
-682
-46% -$10.3K ﹤0.01% 4251
2021
Q3 		$30K Buy
1,484
+1,416
+2,082% +$25K ﹤0.01% 3369
2021
Q2 		$1K Sell
68
-3,396
-98% -$93.6K ﹤0.01% 5161
2021
Q1 		$118K Buy
3,464
+3,110
+879% +$124K ﹤0.01% 2461
2020
Q4 		$14K Buy
+354
New +$16.2K ﹤0.01% 4079

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Tower Research Capital (TRC)'s ABCL Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its AbCellera Biologics (ABCL) stake by 71% in Q1 2026, selling an estimated $51.6K and leaving 5,731 shares worth $20K. The position accounts for ﹤0.01% of the portfolio, ranked #3483.

Tower Research Capital (TRC) first reported a position in ABCL in Q4 2020 and has held it in 22 quarters since. The position peaked at $314K in Q2 2023. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

  • Tower Research Capital (TRC) held 5,731 shares of AbCellera Biologics worth $20K as of Q1 2026.
  • Tower Research Capital (TRC) sold 14,344 AbCellera Biologics shares in Q1 2026, an estimated $51.6K.
  • AbCellera Biologics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3483 holding.
  • Tower Research Capital (TRC) first reported a position in AbCellera Biologics in Q4 2020 and has held it in 22 quarters since.
  • Tower Research Capital (TRC)'s AbCellera Biologics position peaked at $314K in Q2 2023.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.